Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: What is the added value of whole exome sequencing?

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 344-352

  Postel Vinay, Sophie ^a,b   Boursin, Y ^c   Massard, C ^a,b   Hollebecque, A ^a,b   Ileana, E ^a   Chiron, M ^d   Jung, J ^e   Lee, J S ^e   Balogh, Z ^f,g   Adam, J ^f,g   Vielh, P ^f,g   Angevin, E ^a   Lacroix, L ^f,g   Soria, J C ^a,b  

^a Drug Development Unit   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS UMS3655   (France)

^d SANOFI   (France)

^e Oncology Department   (United States)

^f INSERM   (France)

^g NONE   (France)

Author keywords

Array comparative genomic hybridization; Flat profile; Precision medicine; Targeted gene panel sequencing; Whole exome sequencing

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN MLH1; PROTEIN P53;

ADULT; AGED; ARTICLE; ATM GENE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CREBBP GENE; FBXW7 GENE; FEMALE; FGFR2 GENE; FGFR3 GENE; GENE; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MLH1 GENE; NEXT GENERATION SEQUENCING; PDGFRB GENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE VARIANT; TARGETED GENE PANEL SEQUENCING; TP53 GENE; WHOLE EXOME SEQUENCING; CLINICAL TRIAL; COPY NUMBER VARIATION; DNA FINGERPRINTING; DNA SEQUENCE; EXOME; GENETICS; MIDDLE AGED; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; BASE SEQUENCE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA FINGERPRINTING; EXOME; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASMS; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 84961620790     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv570     Document Type: Article

References (44)

1. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189-1197.
2. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
3. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer 2015; 137: 262-266.
4. Tursz T, Andre F, Lazar V et al. Implications of personalized medicine- perspective from a cancer center. Nat Rev Clin Oncol 2011; 8: 177-183.
5. Andre F, McShane LM, Michiels S et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 2011; 8: 171-176.
6. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
7. International Cancer Genome CHudson TJ, Anderson W et al. International network of cancer genome projects. Nature 2010; 464: 993-998.
8. Nik-Zainal S, Van Loo P, Wedge DC et al. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.
9. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724.
10. Rubin AF, Green P. Mutation patterns in cancer genomes. Proc Natl Acad Sci USA 2009; 106: 21766-21770.
11. Arnedos M, Soria JC, Andre F, Tursz T. Personalized treatments of cancer patients:a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat Rev 2014; 40: 1192-1198.
12. De Martino MC, Al Ghuzlan A, Aubert S et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab 2013; 98: 4080-4088.
13. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014; 30: 2114-2120.
14. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
15. Cibulskis K, Lawrence MS, Carter SL et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
16. McKenna A, Hanna M, Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
17. Forbes SA, Beare D, Gunasekaran P et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43: D805-D811.
18. Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 2011; 32: 894-899.
19. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat 2013; 34: E2393-E2402.
20. Cingolani P, Patel VM, Coon M et al. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift. Front Genet 2012; 3: 35.
21. Cingolani P, Platts A, Wang le L et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012; 6: 80-92.
22. Genomes Project C, Abecasis GR, Auton A et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65.
23. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. http://evs.gs.washington.edu/EVS/ (23 September 2015, date last accessed).
24. Van Allen EM, Wagle N, Stojanov P et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20: 682-688.
25. Favero F, Joshi T, Marquard AM et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol 2015; 26: 64-70.
26. Silverberg DM. Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report. BMC Urol 2012; 12: 20.
27. Salazar L, Kashiwada T, Krejci P et al. Fibroblast growth factor receptor 3 interacts with and activates TGFbeta-activated kinase 1 tyrosine phosphorylation and NFkappaB signaling in multiple myeloma and bladder cancer. PLoS One 2014; 9: e86470.
28. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell 2014; 5: 265-296.
29. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43: 875-878.
30. Ferté C, Massard C, Ileana E et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Am Assoc Cancer Res 2014; Abstract CT240.
31. Nik-Zainal S, Alexandrov LB, Wedge DC et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-993.
32. Cancer Genome Atlas Research NWeinstein JN, Collisson EA et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113-1120.
33. Helleday T, Petermann E, Lundin C et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204.
34. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
35. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-322.
36. Arnedos M, Vielh P, Soria JC, Andre F. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 2014; 232: 274-282.
37. Hoadley KA, Yau C, Wolf DM et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158: 929-944.
38. Weisenberger DJ. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest 2014; 124: 17-23.
39. Koutsimpelas D, Pongsapich W, Heinrich U et al. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncol Rep 2012; 27: 1135-1141.
40. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21: 1174-1179.
41. Curtis LJ, Georgiades IB, White S et al. Specific patterns of chromosomal abnormalities are associated with RER status in sporadic colorectal cancer. J Pathol 2000; 192: 440-445.
42. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20.
43. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
44. Yap TA, Gerlinger M, Futreal PA et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps110.